This trial is active, not recruiting.

Condition type 2 diabetes
Treatment alcohol
Phase phase 2
Sponsor The S. Daniel Abraham International Center for Health and Nutrition
Collaborator The Israeli Diabetes Research Group
Start date February 2006
End date December 2006
Trial size 100 participants
Trial identifier NCT00295334, 250505


Our specific aim is to explore the effect of moderate alcohol intake on parameters of glycemic index and lipid profile among patients with type 2 diabetes.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Allocation randomized
Endpoint classification efficacy study
Intervention model parallel assignment
Masking single blind
Primary purpose prevention

Primary Outcomes

adherence, HbA1c, Glc
time frame:

Secondary Outcomes

time frame:

Eligibility Criteria

Male or female participants from 40 years up to 75 years old.

Inclusion Criteria: 1. Age between 40-75 yrs. 2. Alcohol abstainers (less than or equal to 1 drink/week) 3. Established diagnosis of type 2 diabetes. 4. Clinically stable, with no stroke or MI within the last 3 months and no major surgery within the last 3 months. Exclusion Criteria: 1. Taking Insulin >2 injections /day, or with insulin pump. 2. TGs>500 mg/dL. 3. HbA1c >10% 4. Serum creatinine > 2 mg/dl 5. Liver dysfunction (above 2 fold level of ALT and/or AST enzymes) 5. Evidence of severe diabetes complications (such as proliferative retinopathy or renal disease). 6. Patients with autonomic neuropathy manifested as postural hypertension and/or hypoglycemia unawareness. 7. Using drugs that might significantly interact with moderate alcohol. List of drugs will be obtained from pharmacology expert. 8. Presence of active cancer, receiving or had received chemotherapy in last 3 years. 9. Suffering a major illness that might probably require hospitalization (upon physician's evaluation). 10. Clinically assessed as having high potential of addictive behavior as judged by a validated clinical assessment and/or personal or family history of addiction, alcoholism or alcohol abuse. 11. Severe symptoms during run-in as assessed by the physician. 12. Pregnant or lactating women. 13. Participation in another trial in which active intervention is being received. -

Additional Information

Principal investigator Iris Shai, RD PhD
Description Successful long-term control of hyperglycemia decreases the risk for diabetic complications . Although a family history of diabetes is an established risk factor for type 2 diabetes, lifestyle factors also play an important role in its cause . However, physicians are poorly informed about how their patients’ alcohol use affects risk for or management of diabetes. Moderate alcohol consumption has been associated with lower risk of both cardiovascular disease and type 2 diabetes, and is also linked to lower cardiovascular risk among type 2 diabetics. Potential mechanisms have focused primarily on lipid metabolism, coagulation, fibrinolysis, and insulin sensitivity. A recent systematic review of the literature to assess the effect of alcohol consumption on risk for and management and complications of diabetes mellitus suggests that moderate alcohol consumption is associated with a decreased risk for diabetes, whereas heavy alcohol consumption may be associated with an increased risk. Our aim is to assess the effect of moderate alcohol intake on glycemic control and cardiovascular disease mediators among patients with type 2 diabetes.
Trial information was received from ClinicalTrials.gov and was last updated in September 2006.
Information provided to ClinicalTrials.gov by The S. Daniel Abraham International Center for Health and Nutrition.